Microbial efflux systems and inhibitors: Approaches to drug discovery and the challenge of clinical implementation

Open Microbiology Journal

Volumn 7, Issue SPEC.ISSUE.1, 2013, Pages 34-52

  Kourtesi, Christina ^a,b   Ball, Anthony R ^c   Huang, Ying Ying ^d,e   Jachak, Sanjay M ^f   Vera, D Mariano A ^g   Khondkar, Proma ^h   Gibbons, Simon ^h   Hamblin, Michael R ^d,e,i   Tegos, George P ^a,d,e,j  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ATHENS   (Greece)

^c Toxikon Corporation   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

^g UNIVERSIDAD NACIONAL DE MAR DEL PLATA   (Argentina)

^h UNIVERSITY OF LONDON   (United Kingdom)

ⁱ HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

^j UNIVERSITY OF NEW MEXICO   (United States)

more..

Author keywords

Antimicrobial resistance; Biofilms; Dual action antimicrobials; Multidrug efflux systems; Natural efflux pump inhibitors; Photo inactivation; Virulence

Indexed keywords

4,5 CAFFEOYLQUINIC ACID; ALKYLAMINOQUINAZOLINE; ANTIINFECTIVE AGENT; ANTIMICROBIAL CATIONIC PEPTIDE; BACTERIAL PROTEIN; BERBERINE; BREAST CANCER RESISTANCE PROTEIN; CHALCONE; CHLORAMPHENICOL; CIPROFLOXACIN; DRUG METABOLITE; FERULOYL 4' O METHYLDOPAMINE; FULLERENE; FUROCOUMARIN; GALBANIC ACID; GENISTEIN; HYPERICIN; METHYLENE BLUE; MULTIDRUG EXPORT PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; NATURAL PRODUCT; NORFLOXACIN; PROTEIN NOR; QUINAZOLINE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPINOSAN A; TETRACYCLINE; TOLONIUM CHLORIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN;

ANTIMICROBIAL ACTIVITY; DISEASE MODEL; DRUG DETERMINATION; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENTEROCOCCAL INFECTION; FUNGUS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOST PATHOGEN INTERACTION; MICROBIAL EFFLUX SYSTEM; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MYCOBACTERIUM; NONHUMAN; PHENOTYPE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; REVIEW; STAPHYLOCOCCUS INFECTION; STRUCTURE ACTIVITY RELATION;

EID: 84876091746     PISSN: None     EISSN: 18742858     Source Type: Journal    
DOI: 10.2174/1874285801307010034     Document Type: Review

References (223)

1. Binder S, Levitt AM, Sacks JJ, Hughes JM. Emerging infectious diseases: public health issues for the 21st century. Science 1999; 284:1311-3
2. Alekshun M, Levy SB. Molecular mechanisms of antibacterial multidrug resistance. Cell 2007; 128: 1037-50.
3. Piddock L. Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin Microbiol Rev 2006;19: 382-402.
4. Cannon R, Lamping E, Holmes AR, et al. Efflux-mediated antifungal drug resistance. Clin Microbiol Rev 2009; 2: 291-321.
5. Paulsen IT, Chen J, Nelson KE, Saier MHJ. Comparative genomics of microbial drug efflux systems. In: Lewis K, Ed. Microbial multidrug efflux. Norfolk: Horizon Press 2002.
6. Tegos GP, Haynes M, Strouse JJ, et al. Microbial Efflux Inhibition; tactics & strategies. Curr Pharm Des 2011; 17: 1291-302.
7. Ren Q, Paulsen, IT. Comparative analyses of fundamental differences in membrane transport capabilities in prokaryotes and eukaryotes. PLoS Comput Biol 2005; 3: e27.
8. Fletcher JI, Haber M, Henderson MJ, Norris MD. ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer 2010; 10: 147-56.
9. Nikaido H. Multidrug efflux pumps of gram-negative bacteria. J Bacteriol 1996; 178: 5853-9.
10. Li X, Nikaido H. Efflux-mediated drug resistance in bacteria: an update. Drugs 2009; 69:1555-623.
11. Lee A, Mao W, Warren MS, et al. Interplay between efflux pumps may provide either additive or multiplicative effects on drug resistance. J Bacteriol 2000; 182: 3142-50.
12. Tal N, Schuldiner S. A coordinated network of transporters with overlapping specificities provides a robust survival strategy. Proc Natl Acad Sci USA 2009; 106: 9051-6.
13. Takatsuka Y, Chen C, Nikaido H. Mechanism of recognition of compounds of diverse structures by the multidrug efflux pump AcrB of Escherichia coli. Proc Natl Acad Sci USA 2010; 107: 6559-65.
14. Symmons M, Bokma E, Koronakis E, Hughes C, Koronakis V. The assembled structure of a complete tripartite bacterial multidrug efflux pump. Proc Natl Acad Sci USA 2009; 106: 7173-8.
15. Yao X, Kenzaki H, Murakami S, Takada S. Drug export and allosteric coupling in a multidrug transporter revealed by molecular simulations. Nat Commun 2010; 1: 117.
16. Amaral L, Fanning S, Pagès JM. Efflux pumps of gram-negative bacteria: genetic responses to stress and the modulation of their activity by pH, inhibitors, and phenothiazines. Adv Enzymol Relat Areas Mol Biol 2011; 77: 61-108.
17. Su C, Li M, Gu R, et al. Conformation of the AcrB multidrug efflux pump in mutants of the putative proton relay pathway. J Bacteriol 2006; 188: 7290-6.
18. Amaral L, Cerca P, Spengler G, et al. Ethidium bromide efflux by Salmonella: modulation by metabolic energy, pH, ions andphenothiazines. Int J Antimicrob Agents 2011; 38: 140-5.
19. Gibbons S. Phytochemicals for bacterial resistance--strengths, weaknesses and opportunities. Planta Med 2008; 74: 594-602.
20. McAleese F, Petersen P, Ruzin A, et al. A novel MATE family efflux pump contributes to the reduced susceptibility of laboratoryderived Staphylococcus aureus mutants to tigecycline. Antimicrob Agents Chemother 2005; 49:1865-71.
21. Narui K, Noguchi N, Wakasugi K, Sasatsu M. Cloning and characterization of a novel chromosomal drug efflux gene in Staphylococcus aureus. Biol Pharm Bull 2002; 25: 1533-6.
22. Brown M, Skurray RA. Staphylococcal multidrug efflux protein QacA. J Mol Microbiol Biotechnol 2001; 3: 163-70.
23. Xu Z, O'Rourke BA, Skurray RA, Brown MH. Role of transmembrane segment 10 in efflux mediated by the staphylococcal multidrug transport protein QacA. J Biol Chem 2006; 281: 792-9.
24. Jin J, Guffanti AA, Bechhofer DH, Krulwich TA. Tet(L) and tet(K) tetracycline-divalent metal/H+ antiporters: characterization of multiple catalytic modes and a mutagenesis approach to differences in their efflux substrate and coupling ion preferences. J Bacteriol 2002; 184: 4722-32.
25. Jonas BM, Murray BE, Weinstock GM. Characterization of emeA, a NorA homolog and multidrug resistance efflux pump, in Enterococcus faecalis. Antimicrob Agents Chemother 2001; 45: 3574-9.
26. Lewis K. In search of natural substrates and inhibitors of MDR pumps. J Mol Microbiol Biotechnol 2001; 3: 247-54.
27. Tegos G, Stermitz FR, Lomovskaya O, Lewis K. Multidrug pump inhibitors uncover remarkable activity of plant antimicrobials. Antimicrob Agents Chemother 2002; 46: 3133-41.
28. Nordmann P, Naas T, Fortineau N, Poirel L. Superbugs in the coming new decade; multidrug resistance and prospects for treatment of Staphylococcus aureus, Enterococcus spp. and Pseudomonas aeruginosa in 2010. Curr Opin Microbiol 2007;10: 436-40.
29. Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol 2007; 5: 939-51.
30. Poole K. Pseudomonas aeruginosa: resistance to the max. Front Microbiol 2011; 2: 65.
31. Mima T, Kohira N, Li Y, et al. Gene cloning and characteristics of the RND-type multidrug efflux pump MuxABC-OpmB possessing two RND components in Pseudomonas aeruginosa. Microbiology 2009; 155: 3509-17.
32. Mima T, Joshi S, Gomez-Escalada M, Schweizer HP. Identification and characterization of TriABC-OpmH, a triclosan efflux pump of Pseudomonas aeruginosa requiring two membrane fusion proteins. J Bacteriol 2007; 189: 7600-9.
33. Schell M, Zhao P, Wells L. Outer membrane proteome of Burkholderia pseudomallei and Burkholderia mallei from diverse growth conditions. J Proteome Res 2011; 10: 2417-24.
34. Bazzini S, Udine C, Sass A, et al. Deciphering the role of RND efflux transporters in Burkholderia cenocepacia. PLoS ONE 2011; 6: e18902.
35. Ueda O, Wexler HM, Hirai K, Shibata Y, Yoshimura F, Fujimura S. Sixteen homologs of the mex-type multidrug resistance efflux pump in Bacteroides fragilis. Antimicrob Agents Chemother 2005; 49: 2807-15.
36. Damier-Piolle L, Magnet S, Brémont S, Lambert T, Courvalin P. AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii. Antimicrob Agents Chemother 2008; 52: 557-62.
37. Lin L, Ling BD, Li XZ. Distribution of the multidrug efflux pump genes, adeABC, adeDE and adeIJK, and class 1 integron genes in multiple-antimicrobial-resistant clinical isolates of Acinetobacter baumannii-Acinetobacter calcoaceticus complex. Int J Antimicrob Agents 2009; 33: 27-32.
38. Cortez-Cordova J, Kumar A. Activity of the efflux pump inhibitor phenylalanine-arginine β-naphthylamide against the AdeFGH pump of Acinetobacter baumannii. Int J Antimicrob Agents 2011; 37: 420-4.
39. Matsuo T, Chen J, Minato Y, et al. SmdAB, a heterodimeric ABC-Type multidrug efflux pump, in Serratia marcescens. J Bacteriol 2008; 190: 648-54.
40. Tikhonova E, Devroy VK, Lau SY, Zgurskaya HI. Reconstitution of the Escherichia coli macrolide transporter: the periplasmic membrane fusion protein MacA stimulates the ATPase activity of MacB. Mol Microbiol 2007; 63: 895-910.
41. Rouquette-Loughlin C, Balthazar JT, Shafer WM. Characterization of the MacA-MacB efflux system in Neisseria gonorrhoeae. J Antimicrob Chemother 2005; 56: 856-60.
42. Santiviago C, Fuentes JA, Bueno SM, et al. The Salmonella enterica sv. Typhimurium smvA, yddG and ompD (porin) genes are required for the efficient efflux of methyl viologen. Mol Microbiol 2002; 46: 687-98.
43. Nishino K, Yamaguchi A. Analysis of a complete library of putative drug transporter genes in Escherichia coli. J Bacteriol 2001; 183: 5803-12.
44. Rodríguez-Martínez J, Cano ME, Velasco C, Martínez-Martínez L, Pascual A. Plasmid-mediated quinolone resistance: an update. J Infect Chemother 2011; 17: 149-82.
45. Coyne S, Courvalin P, Périchon B. Efflux-mediated antibiotic resistance in Acinetobacter spp. Antimicrob Agents Chemother 2011; 55: 947-53.
46. Rajamohan G, Srinivasan VB, Gebreyes WA. Molecular and functional characterization of a novel efflux pump, AmvA, mediating antimicrobial and disinfectant resistance in Acinetobacter baumannii. J Antimicrob Chemother 2010; 65: 1919-25.
47. He G, Zhang C, Crow RR, et al. SugE, a new member of the SMR family of transporters, contributes to antimicrobial resistance in Enterobacter cloacae. Antimicrob Agents Chemother 2011; 55: 3954-7.
48. Da Silva P, Von Groll A, Martin A, Palomino JC. Efflux as a mechanism for drug resistance in Mycobacterium tuberculosis. FEMS Immunol Med Microbiol 2011; 63: 1-9.
49. Aínsa J, Blokpoel MC, Otal I, Young DB, De Smet KA, Martín C. Molecular cloning and characterization of Tap, a putative multidrug efflux pump present in Mycobacterium fortuitum and Mycobacterium tuberculosis. J Bacteriol 1998; 180: 5836-43.
50. De Rossi E, Arrigo P, Bellinzoni M, et al. The multidrug transporters belonging to major facilitator superfamily in Mycobacterium tuberculosis. Mol Med 2002; 8: 714-24.
51. Balganesh M, Dinesh N, Sharma S, Kuruppath S, Nair AV, Sharma U. Efflux Pumps of Mycobacterium tuberculosis play a significant role in anti-tuberculosis activity of potential drug candidates. Antimicrob Agents Chemother 2012; 56: 2643-51.
52. Choudhuri B, Bhakta S, Barik R, Basu J, Kundu M, Chakrabarti P. Overexpression and functional characterization of an ABC (ATP-binding cassette) transporter encoded by the genes drrA and drrB of Mycobacterium tuberculosis. Biochem J 2002; 367: 279-85.
53. Danilchanka O, Mailaender C, Niederweis M. Identification of a novel multidrug efflux pump of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2008; 52: 2503-11.
54. Hao P, Shi-Liang Z, Ju L, et al. The role of ABC efflux pump, Rv1456c-Rv1457c-Rv1458c, from Mycobacterium tuberculosis clinical isolates in China. Folia Microbiol (Praha) 2011; 56: 549-53.
55. Buroni S, Manina G, Guglierame P, Pasca MR, Riccardi G, De Rossi E. LfrR is a repressor that regulates expression of the efflux pump LfrA in Mycobacterium smegmatis. Antimicrob Agents Chemother 2006; 50: 4044-52.
56. Li X, Zhang L, Nikaido H. Efflux pump-mediated intrinsic drug resistance in Mycobacterium smegmatis. Antimicrob Agents Chemother 2004; 48: 2415-23.
57. De Rossi E, Branzoni M, Cantoni R, Milano A, Riccardi G, Ciferri O. mmr, a Mycobacterium tuberculosis gene conferring resistance to small cationic dyes and inhibitors. J Bacteriol 1998; 180: 6068-71.
58. Lamping E, Baret PV, Holmes AR, Monk BC, Goffeau A, Cannon RD. Fungal PDR transporters: Phylogeny, topology, motifs and function. Fungal Genet Biol 2010; 47: 127-42.
59. Paumi CM, Chuck M, Snider J, Stagljar I, Michaelis S. ABC transporters in Saccharomyces cerevisiae and their interactors: new technology advances the biology of the ABCC (MRP) subfamily. Microbiol Mol Biol Rev 2009; 73: 577-93.
60. Holmes AR, Lin YH, Niimi K, et al. ABC transporter Cdr1p contributes more than Cdr2p does to fluconazole efflux in fluconazole-resistant Candida albicans clinical isolates. Antimicrob Agents Chemother 2008; 52(11): 3851-62.
61. Cannon RD, Lamping E, Holmes AR, et al. Efflux-mediated antifungal drug resistance. Clin Microbiol Rev 2009; 22: 291-321.
62. Holmes AR, Tsao S, Ong SW, et al. Heterozygosity and functional allelic variation in the Candida albicans efflux pump genes CDR1 and CDR2. Mol Microbiol 2006; 62: 170-86.
63. Hamblin M, Hasan T. Photodynamic therapy: a new antimicrobial approach to infectious disease? Photochem Photobiol Sci 2004; 3(5): 436-50.
64. Mitton D, Ackroyd R. A brief overview of photodynamic therapy in Europe. Photodiagnosis Photodyn Ther 2008; 5: 103-11.
65. St. Denis T, Dai T, Izikson A, et al. All you need is light antimicrobial photoinactivation as an evolving and emerging discovery strategy against infectious disease. Virulence 2011; 2: 1-12.
66. Wainwright M, Byrne MN, Gattrell MA. Phenothiazinium-based photobactericidal materials. J Photochem Photobiol B 2006; 84(3): 227-30.
67. Huang L, Huang YY, Mroz P, et al. Stable synthetic cationic bacteriochlorins as selective antimicrobial photosensitizers. Antimicrob Agents Chemother 2010; 54: 3834-41.
68. Castano A, Demidova TN, Hamblin MR. Mechanisms in photodynamic therapy: part one-photosensitizers, photochemistry and cellular localization. Photodiagnosis Photodyn Ther 2004; 1: 279-93.
69. Schafer M, Schmitz C, Facius R, et al. Systematic study of parameters influencing the action of Rose Bengal with visible light on bacterial cells: comparison between the biological effect and singlet-oxygen production. Photochem Photobiol 2000; 71: 514-23.
70. Harris F, Chatfield LK, Phoenix DA. Phenothiazinium based photosensitisers--photodynamic agents with a multiplicity of cellular targets and clinical applications. Curr Drug Targets 2005; 6: 615-27.
71. Tegos G, Demidova TN, Arcila-Lopez D, et al. Cationic fullerenes are effective and selective antimicrobial photosensitizers. Chem Biol 2005; 12: 1127-35.
72. Huang L, Terakawa M, Zhiyentayev T, et al. Innovative cationic fullerenes as broad-spectrum light-activated antimicrobials. Nanomedicine 2010; 6: 442-52.
73. Fisher W, Partridge WP Jr, Dees C, Wachter EA. Simultaneous two-photon activation of type-I photodynamic therapy agents. Photochem Photobiol 1997; 66: 141-55.
74. Plaetzer K, Krammer B, Berlanda J, Berr F, Kiesslich T. Photophysics and Photochemistry of photodynamic therapy: fundamental aspects. Lasers Med Sci 2009; 24: 259-68.
75. Maisch T. A new strategy to destroy antibiotic resistant microorganisms: antimicrobial photodynamic treatment. Mini Rev Med Chem 2009; 9: 974-83.
76. Paterson M, Bergendahl LT. Computational Modelling of the Steps Involved in Photodynamic Therapy. In: Sahas S, Ed. Molecular Photochemistry-Various Aspects 2012.
77. Quartarolo A, Russo N. On the potential use of squaraine derivatives as photosensitizers in photodynamic therapy: a tddft and ricc2 survey. J Chem Theory Comput 2009; 5: 1849-57.
78. Serrano-Perea J, Serrano-Andrés L, Merchán M. A theoretical insight into the photophysics of psoralen. J Chem Phys 2006; 124: 124502.
79. Glusko CA, Previtali CM, Vera DMA, Chesta CA, Montejano HA. An experimental and theoretical study on the photophysical properties of methylene green. Dyes Pigm 2011; 90: 28-35.
80. Shen L. Theoretical investigation on the triplet excited state properties of the porphyrin-related photosensitizers and the implications in illustrating their photosensitization mechanisms. J Mol Struct 2008; 862: 130-2.
81. Quartarolo A, Lanzo I, Sicilia E, Russo N. Can phthalocyanines and their substituted alpha-para-(methoxy)phenyl derivatives act as photosensitizers in photodynamic therapy? A TD-DFT study. Phys Chem Chem Phys 2009; 11: 4586-92.
82. Zhao X, Zheng Z, Feng S, Shi Z, Chen D. A TD-DFT Study on the Photo-Physicochemical properties of chrysophanol from Rheum. Int J Mol Sci 2009; 10: 3186-93.
83. Badaeva E, Timofeeva TV, Masunov A, Tretiak A. Role of donoracceptor strengths and separation on the two-photon absorption response of cytotoxic dyes: A TD-DFT Study. J Phys Chem A 2005; 109: 7276-84.
84. Sun W, Li Z, Badaeva E, et al. Tuning Photophysics and nonlinear absorption of bipyridyl Platinum(II) Bisstilbenylacetylide complexes by auxiliary substituents. J Phys Chem A 2012; 116(20): 4878-89.
85. Arnbjerg J, Jiménez-Banzo A, Paterson MJ, et al. Two-Photon Absorption in tetraphenylporphycenes: are porphycenes better candidates than porphyrins for providing optimal optical properties for two-photon photodynamic therapy? J Am Chem Soc 2007; 129: 5188-99.
86. Segalla A, Borsarelli CD, Braslavsky SE, et al. Photophysical, photochemical and antibacterial photosensitizing properties of a novel octacationic Zn(II)-phthalocyanine. Photochem Photobiol Sci 2002; 1: 641-8.
87. Bakalova R, Ohba H, Zhelev Z, et al. Quantum Dot anti-CD Conjugates: Are they potential photosensitizers or potentiators of classical photosensitizing agents in photodynamic therapy of cancer? Nano Lett 2004; 4: 1567-73.
88. Nombona N, Antunes E, Chidawanyika W, Kelyi P, Tshentu Z, Nyokong T. Synthesis, photophysics and photochemistry of phthalocyanine-e{open}-polylysine conjugates in the presence of metal nanoparticles against Staphylococcus aureus. J Photochem Photobiol A Chem 2012; 233: 24-33.
89. Perni S, Prokopovich P, Pratten J, Parkin IP, Wilson M. Nanoparticles: their potential use in antibacterial photodynamic therapy. Photochem Photobiol Sci 2011; 10: 712-20.
90. Dutta S, Ongarora BG, Li H, Vicente Mda G, Kolli BK, Chang KP. Intracellular targeting specificity of novel phthalocyanines assessed in a host-parasite model for developing potential photodynamic medicine. PLoS ONE 2011; 6: e20786.
91. Robey R, Steadman K, Polgar O, Bates SE. ABCG2-mediated transport of photosensitizers: potential impact on photodynamic therapy. Cancer Biol Ther 2005; 4: 187-94.
92. Robey R, Fetsch PA, Polgar O, Dean M, Bates SE. The livestock photosensitizer, phytoporphyrin (phylloerythrin), is a substrate of the ATP-binding cassette transporter ABCG2. Res Vet Sci 2006; 81: 345-9.
93. Ogino T, Kobuchi H, Munetomo K, et al. Serum-dependent export of protoporphyrin IX by ATP-binding cassette transporter G2 in T24 cells. Mol Cell Biochem 2011; 58: 297-307.
94. Morgan J, Jackson J, Zheng X, Pandey SK, Pandey RK. Substrate affinity of photosensitizers derived from chlorophyll-a: The ABCG2 transporter affects the phototoxic response of side population stem cell-like cancer cells to photodynamic therapy. Mol Pharm 2010; 7: 1789-804.
95. Jendzelovský R, Mikes J, Koval' J, et al. Drug efflux transporters, MRP1 and BCRP, affect the outcome of hypericin-mediated photodynamic therapy in HT-29 adenocarcinoma cells. Photochem Photobiol Sci 2009; 8: 1716-23.
96. Merlin J, Gautier H, Barberi-Heyob M, Teiten MH, Guillemin F. The multidrug resistance modulator SDZ-PSC 833 potentiates the photodynamic activity of chlorin e6 independently of P-glycoprotein in multidrug resistant human breast adenocarcinoma cells. Int J Oncol 2003; 22: 733-9.
97. Wang E, Casciano CN, Clement RP, Johnson WW. Inhibition of P-glycoprotein transport function by grapefruit juice psoralen. Pharm Res 2001; 18: 432-8.
98. Adigbli D, Wilson DG, Farooqui N, et al. Photochemical internalisation of chemotherapy potentiates killing of multidrug resistant breast and bladder cancer cells. Br J Cancer 2007; 97: 502-12.
99. Stermitz F, Lorenz P, Tawara JN, Zenewicz LA, Lewis K. Synergy in a medicinal plant: antimicrobial action of berberine potentiated by 5'-methoxyhydnocarpin, a multidrug pump inhibitor. Proc Natl Acad Sci USA 2000; 97: 1433-7.
100. Tegos G, Hamblin MR. Phenothiazinium antimicrobial photosensitizers are substrates of bacterial multidrug resistance pumps. Antimicrob Agents Chemother 2006; 50: 196-203.
101. Tseng SP, Teng LJ, Chen CT, et al. Toluidine blue O photodynamic inactivation on multidrug-resistant Pseudomonas aeruginosa. Lasers Surg Med 2009; 41: 391-7.
102. Prates R, Kato IT, Ribeiro MS, Tegos GP, Hamblin MR. Influence of multidrug efflux systems on methylene blue-mediated photodynamic inactivation of Candida albicans. J Antimicrob Chemother 2011; 66: 1525-32.
103. Vera DMA, Haynes MH, Ball AR, et al. Strategies to potentiate antimicrobial photoinactivation by overcoming resistant phenotypes. Photochem Photobiol 2012; 88: 499-511
104. Sabatini S, Kaatz GW, Rossolini GM, Brandini D, Fravolini A. From phenothiazine to 3-phenyl-1,4-benzothiazine derivatives as inhibitors of the Staphylococcus aureus NorA multidrug efflux pump. J Med Chem 2008; 51: 4321-30.
105. Amaral L, Martins M, Viveiros M, Molnar J, Kristiansen JE. Promising therapy of XDR-TB/MDR-TB with thioridazine an inhibitor of bacterial efflux pumps. Curr Drug Targets 2008; 9: 816-9.
106. Bailey A, Paulsen IT, Piddock LJ. RamA confers multidrug resistance in Salmonella enterica via increased expression of acrB, which is inhibited by chlorpromazine. Antimicrob Agents Chemother 2008; 10: 3604-11.
107. Tatsumi R, Wachi M. TolC-dependent exclusion of porphyrins in Escherichia coli. J Bacteriol 2008;190: 6228-33.
108. Fernandez A, Lechardeur D, Derré-Bobillot A, Couvé E, Gaudu P, Gruss A. Two coregulated efflux transporters modulate intracellular heme and protoporphyrin IX availability in Streptococcus agalactiae. PLoS Pathog 2010; 6: e1000860.
109. Grinholc M, Zawacka-Pankau J, Gwizdek-Wiśniewska A, Bielawski KP. Evaluation of the role of the pharmacological inhibition of Staphylococcus aureus multidrug resistance pumps and the variable levels of the uptake of the sensitizer in the strain dependent response of Staphylococcus aureus to PPArg(2)-based photodynamic inactivation. Photochem Photobiol 2010; 86: 1118-26.
110. Grkovic S, Brown MH, Skurray RA. Regulation of Bacterial Drug Export Systems. Microbiol Mol Biol Rev 2002; 66: 671-701.
111. Kisker C, Hinrichs W, Tovar K, Hillen W, Saenger W. The complex formed between tet repressor and tetracycline-mg2+ reveals mechanism of antibiotic resistance. J Mol Biol 1995; 247: 60.
112. Bohnert JA, Karamian B, Nikaido H. Optimized Nile Red efflux assay of AcrAB-TolC multidrug efflux system shows competition between substrates. Antimicrob Agents Chemother 2010; 54: 3770-5.
113. Martins M, Viveiros M, Couto I, et al. Identification of efflux pump-mediated multidrug-resistant bacteria by the ethidium bromide-agar cartwheel method. In Vivo 2011; 25: 171-8.
114. Viveiros M, Rodrigues L, Martins M, et al. Evaluation of efflux activity of bacteria by a semi-automated fluorometric system. Methods Mol Biol 2010; 642: 159-72.
115. Kalle A, Rizvi A. Inhibition of bacterial multidrug resistance by celecoxib, a cyclooxygenase-2 inhibitor. Antimicrob Agents Chemother 2011; 55: 439-42.
116. Matsumoto Y, Hayama K, Sakakihara S, et al. Evaluation of multidrug efflux pump inhibitors by a new method using microfluidic channels. PLoS ONE 2011; 6: e18547.
117. Leitner I, Nemeth J, Feurstein T, et al. The third-generation P-glycoprotein inhibitor tariquidar may overcome bacterial multidrug resistance by increasing intracellular drug concentration. J Antimicrob Chemother 2011; 66: 834-9.
118. Mahamoud A, Chevalier J, Baitiche M, Adam E, Pagès JM. An alkylaminoquinazoline restores antibiotic activity in Gram-negative resistant isolates. Microbiology 2011; 157: 566-71.
119. Eliopoulos GM, Moellering RC. Antibiotics in laboratory medicine. In: Lorian V, Ed. Antibiotics in laboratory medicine. Baltimore, MD: Williams & Wilkins Co. 1991; pp. 432-92.
120. Kamicker B, Sweeney MT, Kaczmarek F, et al. Bacterial efflux pump inhibitors. Methods Mol Med 2008; 142: 187-200.
121. Odds F. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 2003; 52: 1.
122. Ackerman B, Vannier AM, Eudy EB. Analysis of vancomycin time-kill studies with Staphylococcus species by using a curve stripping program to describe the relationship between concentration and pharmacodynamic response. Antimicrob Agents Chemother 1992; 36: 1766-9.
123. Sharma S, Kumar M, Sharma S, Nargotra A, Koul S, Khan IA. Piperine as an inhibitor of Rv1258c, a putative multidrug efflux pump of Mycobacterium tuberculosis. J Antimicrob Chemother 2010; 65: 1694-701.
124. Yin Y, He X, Szewczyk P, Nguyen T, Chang G. Structure of the multidrug transporter EmrD from Escherichia coli. Science 2006; 312: 741-4.
125. Huang Y, Lemieux MJ, Song J, Auer M, Wang DN. Structure and Mechanism of the Glycerol-3-Phosphate Transporter from Escherichia coli. Science 2003; 301: 616-20.
126. Aller S, Yu J, Ward A, et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 2009; 323:1718-22.
127. Koronakis V, Sharff A, Koronakis E, Luisi B, Hughes C. Crystal structure of the bacterial membrane protein TolC central to multidrug efflux and protein export. Nature 2000; 405: 914-9.
128. Sennhauser G, Bukowska MA, Briand C, Grütter MG. Crystal structure of the multidrug exporter MexB from Pseudomonas aeruginosa. J Mol Biol 2009; 389: 134-45.
129. Phan G, Benabdelhak H, Lascombe MB, et al. Structural and dynamical insights into the opening mechanism of P. aeruginosa OprM channel. Structure 2010; 18: 507-17.
130. Akama H, Matsuura T, Kashiwagi S, et al. Crystal structure of the membrane fusion protein, MexA, of the multidrug transporter in Pseudomonas aeruginosa. J Biol Chem 2004; 279: 25939-42.
131. Yum S, Xu Y, Piao S, et al. Crystal structure of the periplasmic component of a tripartite macrolide-specific efflux pump. J Mol Biol 2009; 387: 1286-97.
132. He X, Szewczyk P, Karyakin A, et al. Structure of a cation-bound multidrug and toxic compound extrusion transporter. Nature 2010; 467: 991-4.
133. Brincat J, Carosati E, Sabatini S, et al. Discovery of novel inhibitors of the NorA multidrug transporter of Staphylococcus aureus. J Med Chem 2011; 54: 354-65.
134. Medina-Franco1 JL, Martínez-Mayorga K, Bender A, Scior T. Scaffold diversity analysis of compound data sets using an entropy based measure. QSAR Comb Sci 2009, 28, 1551-1560.
135. Nargotra A, Sharma S, Koul JL, et al. Quantitative structure activity relationship (QSAR) of piperine analogsfor bacterial NorA efflux pump inhibitors. Eur J Med Chem 2009; 44: 4128-35.
136. Dai Y, Zhang X, Zhang X, Wang H, Lu Z. DFT and GA studies on the QSAR of 2-aryl-5-nitro-1H-indole derivatives as NorA efflux pump inhibitors. J Mol Model 2008;14: 807-12.
137. Edwards B, Kuckuck FW, Prossnitz ER, Ransom JT, Sklar LA. HTPS flow cytometry: a novel platform for automated high throughput drug discovery and characterization. J Biomol Screen 2001; 6: 83-90.
138. Winter S, Lovato DM, Khawaja HM, et al. High-throughput screening for daunorubicin-mediated drug resistance identifies mometasone furoate as a novel ABCB1-reversal agent. J Biomol Screen 2008; 13: 185-93.
139. Ivnitski-Steele I, Larson RS, Lovato DM, et al. High-throughput flow cytometry to detect selective inhibitors of ABCB1, ABCC1, and ABCG2 transporters. Assay Drug Dev Technol 2008; 2: 263-76.
140. Ivnitski-Steele I, Holmes AR, Lamping E, Monk BC, Cannon RD, Sklar LA. Identification of Nile red as a fluorescent substrate of the Candida albicans ATP-binding cassette transporters Cdr1p and Cdr2p and the major facilitator superfamily transporter Mdr1p. Anal Biochem 2009; 394: 87-91.
141. Holmes A, Keniya MV, Ivnitski-Steele I, et al. The monoamine oxidase A inhibitor clorgyline is a broad-spectrum inhibitor of fungal ABC and MFS transporter efflux pump activities which reverses the azole resistance of Candida albicans and Candida glabrata clinical isolates. Antimicrob Agents Chemother 2012; 56: 1508-15.
142. WHO. World health organization reports highest rates of drug-resistant tuberculosis to date. Available at: wwwwhoint/tb/features_archive/drs_factsheetpdf [accessed 10 October 2010] 2008.
143. da Silva P, Von Groll A, Martin A, Palomino JC. Efflux as a mechanism for drug resistance in Mycobacterium tuberculosis. FEMS Immunol Med Microbiol 2011; 63: 1-9.
144. Barrett J. MC-207110 Daiichi seiyaku/microcide pharmaceuticals. Curr Opin Investig Drugs 2001; 2: 212-5.
145. Kern WV, Steinke P, Schumacher A, Schuster S, von Baum H, Bohnert JA. Effect of 1-(1-naphthylmethyl)-piperazine, a novel putative efflux pump inhibitor, on antimicrobial drug susceptibility in clinical isolates of Escherichia coli. J Antimicrob Chemother 2006; 57: 339-43.
146. Coban AY, Tanniverdi Cayci Y, Erturan Z, Durupinar B. Effects of efflux pump inhibitors phenyl-arginine-beta-naphthylamide and 1-(1-naphthylmethyl)-piperazine on the antimicrobial susceptibility of Pseudomonas aeruginosa isolates from cystic fibrosis patients. J Chemother 2009; 21: 592-4.
147. Chevalier J, Bredin J, Mahamoud A, Malléa M, Barbe J, Pagès JM. Inhibitors of antibiotic efflux in resistant Enterobacter aerogenes and Klebsiella pneumoniae strains. Antimicrob Agents Chemother 2004; 48: 1043-6.
148. Li B, Yao Q, Pan XC, et al. Artesunate enhances the antibacterial effect of {beta}-lactam antibiotics against Escherichia coli by increasing antibiotic accumulation via inhibition of the multidrug efflux pump system AcrAB-TolC. J Antimicrob Chemother 2011; 66: 769-77.
149. Tegos G. Substrates and Inhibitors of microbial efflux pumps; Redifine the Role of Plant Antimicrobials. In: Mahendra Rai CMC, Ed. Naturally occurring bioactive compounds: a new and safe alternative for control of pests and microbial diseases. Cambridge: Cambridge University Press; 2006.
150. Garvey M, Rahman MM, Gibbons S, Piddock LJ. Medicinal plant extracts with efflux inhibitory activity against Gram-negative bacteria. Int J Antimicrob Agents 2011; 37: 145-51.
151. Zhou X, Jia F, Liu X, Wang Y. Total Alkaloids of sophorea alopecuroides-induced down-regulation of acrab-tolc efflux pump reverses susceptibility to ciprofloxacin in clinical multidrug resistant escherichia coli isolates. Phytother Res 2012; 26: 1637-43.
152. Kino T, Hatanaka H, Hashimoto M, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo) 1987; 40: 1249-55.
153. Tanabe K, Lamping E, Adachi K, et al. Inhibition of fungal ABC transporters by unnarmicin A and unnarmicin C, novel cyclic peptides from marine bacterium. Biochem Biophys Res Commun 2007; 364: 990-5.
154. Oku N, Kawabata K, Adachi K, Katsuta A, Shizuri Y. Unnarmicins A and C, new antibacterial depsipeptides produced by marine bacterium Photobacterium sp. MBIC06485. J Antibiot (Tokyo) 2008; 61: 11-7.
155. Digirolamo J, Li XC, Jacob MR, Clark AM, Ferreira D. Reversal of fluconazole resistance by sulfated sterols from the marine sponge Topsentia sp. J Nat Prod 2009; 72: 1524-8.
156. Hiraga K, Yamamoto S, Fukuda H, Hamanaka N, Oda K. Enniatin has a new function as an inhibitor of Pdr5p, one of the ABC transporters in Saccharomyces cerevisiae. Biochem Biophys Res Commun 2005; 328: 1119-25.
157. Lee M, Galazzo J, Staley AL, et al. Microbial fermentation-derived inhibitors of efflux-pump-mediated drug resistance. Farmaco 2001; 56: 81-5.
158. Tegos G, Masago K, Aziz F, Higginbotham A, Stermitz FR, Hamblin MR. Inhibitors of bacterial multidrug efflux pumps potentiate antimicrobial photoinactivation. Antimicrob Agents Chemother 2008; 52(9): 3202-9.
159. Klyachko K, Schuldiner S, Neyfakh AA. Mutations affecting substrate specificity of the Bacillus subtilis multidrug transporter BMR J Bacteriol 1997; 179: 2189-93.
160. Ahmed M, Borsch C, Neyfakh AA, Schuldner S. Mutants of Bacillus subtilis multidrug transporter Bmr with altered sensitivity to the antihypertensive alkaloid reserpine. J Biol Chem 1993; 268: 11086-9.
161. Garvey M, Piddock LJ. The efflux pump inhibitor reserpine selects multidrug-resistant Streptococcus pneumoniae strains that overexpress the ABC transporters PatA and PatB. Antimicrob Agents Chemother 2008; 52: 1677-85.
162. Ball A, Casadei G, Samosorn S, et al. Conjugating berberine to a multidrug efflux pump inhibitor creates an effective antimicrobial. ACS Chem Biol 2006; 1: 594-600.
163. Samosorn S, Tanwirat B, Muhamad N, et al. Antibacterial activity of berberine-NorA pump inhibitor hybrids with a methylene ether linking group. Bioorg Med Chem 2009; 17: 3866-72.
164. Tomkiewicz D, Casadei G, Larkins-Ford J, et al. Berberine-INF55 (5-nitro-2-phenylindole) hybrid antimicrobials: effects of varying the relative orientation of the berberine and INF55 components. Antimicrob Agents Chemother 2010; 54: 3219-24.
165. Martinez J, Sánchez MB, Martínez-Solano L, et al. Functional role of bacterial multidrug efflux pumps in microbial natural ecosystems. FEMS Microbiol Rev 2009; 33: 430-49.
166. Apidianakis Y, Mindrinos MN, Xiao W, et al. Involvement of skeletal muscle gene regulatory network in susceptibility to wound infection following trauma. PLoS ONE 2007; 2: e1356.
167. Apidianakis Y, Que YA, Xu W, et al. Down-regulation of glutatione S-transferase alpha 4 (hGSTA4) in the muscle of thermally injured patients is indicative of susceptibility to bacterial infection. FASEB J 2012; 26: 730-7.
168. Fuchs B, O'Brien E, Khoury JB, Mylonakis E. Methods for using Galleria mellonella as a model host to study fungal pathogenesis. Virulence 2010; 1: 475-82.
169. Sánchez P, Linares JF, Ruiz-Díez B, et al. Fitness of in vitro selected Pseudomonas aeruginosa nalB and nfxB multidrug resistant mutants. J Antimicrob Chemother 2002; 50: 657-64.
170. Olivares J, Alvarez-Ortega C, Linares JF, Rojo F, Köhler T, Martínez JL. Overproduction of the multidrug efflux pump MexEF-OprN does not impair Pseudomonas aeruginosa fitness in competition tests, but produces specific changes in bacterial regulatory networks. Environ Microbiol 2012; 14: 1968-8.
171. O'Quinn A, Wiegand EM, Jeddeloh JA. Burkholderia pseudomallei kills the nematode Caenorhabditis elegans using an endotoxin mediated paralysis. Cell Microbiol 2001; 3: 381-93.
172. Bialek S, Lavigne JP, Chevalier J, et al. Membrane efflux and influx modulate both multidrug resistance and virulence of Klebsiella pneumoniae in a Caenorhabditis elegans model. Antimicrob Agents Chemother 2010; 54: 4373-8.
173. Maeda T, García-Contreras R, Pu M, et al. Quorum quenching quandary: resistance to antivirulence compounds. ISME J 2012; 6: 493-501.
174. Bailey A, Ivens A, Kingsley R, Cottell JL, Wain J, Piddock LJ. RamA, a member of the AraC/XylS family, influences both virulence and efflux in Salmonella enterica serovar Typhimurium. J Bacteriol 2010;192:1607-16.
175. Thakur J, Arthanari H, Yang F, et al. A nuclear receptor-like pathway regulating multidrug resistance in fungi. Nature 2008; 452: 604-9.
176. Ahmad S, Hunter L, Qin A, Mann BJ, van Hoek ML. Azithromycin effectiveness against intracellular infections of Francisella. BMC Microbiol 2010;10:123.
177. Salunkhe P, Smart CH, Morgan JA, et al. A cystic fibrosis epidemic strain of Pseudomonas aeruginosa displays enhanced virulence and antimicrobial resistance. J Bacteriol 2005; 187: 4908-20.
178. Adams K, Takaki K, Connolly LE, et al. Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism. Cell 2011; 145: 39-53.
179. Mirza Z, Kumar A, Kalia NP, Zargar A, Khan IA. Piperine as an inhibitor of the MdeA efflux pump of Staphylococcus aureus. J Med Microbiol 2011; 60: 1472-8.
180. Sánchez-Gómez S, Japelj B, Jerala R, et al. Structural features governing the activity of lactoferricin-derived peptides that act in synergy with antibiotics against Pseudomonas aeruginosa in vitro and in vivo. Antimicrob Agents Chemother 2011; 55: 218-28.
181. Hayama K, Ishibashi H, Ishijima SA, et al. A d-octapeptide drug efflux pump inhibitor acts synergistically with azoles in a murine oral candidiasis infection model. FEMS Microbiol Lett 2012; 328: 130-7.
182. Hashimoto M, Prates RA, Kato IT, Núñez SC, Courrol LC, Ribeiro MS. Antimicrobial photodynamic therapy on drug-resistant pseudomonas aeruginosa-induced infection. An in vivo study. Photochem Photobiol 2012; 88: 590-5.
183. Ding Y, Onodera Y, Lee JC, Hooper DC. NorB, an efflux pump in Staphylococcus aureus strain MW2, contributes to bacterial fitness in abscesses. J Bacteriol 2008; 190: 7123-9.
184. Pérez A, Poza M, Fernández A, et al. Involvement of the AcrAB TolC efflux pump in the resistance, fitness and virulence of Enterobacter cloacae. Antimicrob Agents Chemother 2012; 56: 2084-90
185. Platz G, Bublitz DC, Mena P, Benach JL, Furie MB, Thanassi DG. A tolC mutant of Francisella tularensis is hypercytotoxic compared to the wild type and elicits increased proinflammatory responses from host cells. Infect Immun 2010; 78: 1022-31.
186. Gil H, Platz GJ, Forestal CA, et al. Deletion of TolC orthologs in Francisella tularensis identifies roles in multidrug resistance and virulence. Proc Natl Acad Sci USA 2006; 103: 12897-902.
187. Kadzhaev K, Zingmark C, Golovliov I, et al. Identification of genes contributing to the virulence of Francisella tularensis SCHU S4 in a mouse intradermal infection model. PLoS ONE 2009; 4(5): e5463.
188. Fiamegos Y, Kastritis PL, Exarchou V, et al. Antimicrobial and efflux pump inhibitory activity of caffeoylquinic acids from Artemisia absinthium against gram-positive pathogenic bacteria. PLoS ONE 2011; 6: e18127.
189. Belofsky G, Carreno R, Lewis K, Ball A, Casadei G, Tegos GP. Metabolites of the smoke tree, Dalea spinosa, potentiate antibiotic activity against multidrug-resistant Staphylococcus aureus. J Nat Prod 2006; 69: 261-4.
190. Michalet S, Cartier G, David B, et al. N-caffeoylphenalkylamide derivatives as bacterial efflux pump inhibitors. Bioorg Med Chem Lett 2007; 17: 1755-8.
191. Belofsky G, Percivil D, Lewis K, Tegos G, Ekart J. Phenolic Metabolites of Dalea versicolor that Enhance Antibiotic Activity Against Multi-Drug Resistant Bacteria. J Nat Prod 2004; 67: 481-4.
192. Abulrob AN, Suller MTE, Gumbleton M, Simons C, Russell A. Identification and biological evaluation of grapefruit oil components as potential novel efflux pump modulators in methicillin-resistant Staphylococcus aureus bacterial strains. Phytochemistry 2004; 65: 3021-7.
193. Fazly Bazzaz BS, Iranshahi M, Naderinasa M, Hajian S, Sabeti Z, Masumi E. Evaluation of the effects of galbanic acid from Ferula szowitsiana and conferol from F. badrakema, as modulators of multi-drug resistance in clinical isolates of Escherichia coli and Staphylococcus aureus. Res Pharm Sci 2010; 5: 21-8.
194. Fujita M, Shiota S, Kuroda T, et al. Remarkable synergies between baicalein and tetracycline, and baicalein and beta-lactams against methicillin-resistant Staphylococcus aureus. Microbiol Immunol 2005; 49: 391-6.
195. Stermitz F, Scriven LN, Tegos G, Lewis K. Two flavonols from Artemisa annua which potentiate the activity of berberine and norfloxacin against a resistant strain of Staphylococcus aureus. Planta Med 2002; 68: 1140-1.
196. Falcão-Silva V, Silva DA, Souza Mde F, Siqueira-Junior JP. Modulation of drug resistance in Staphylococcus aureus by a kaempferol glycoside from Herissantia tiubae (Malvaceae). Phytother Res 2009; 10: 1367-70.
197. Stermitz F, Tawara-Matsuda J, Lorenz P, Mueller P, Zenewicz L, Lewis K. 5-0-Methoxyhydnocarpin-D and pheophorbide A: Berberis species components that potentiate berberine growth inhibition of resistant Staphylococcus aureus. J Nat Prod 2000; 63: 1146-9.
198. Morel C, Stermitz F, Tegos G, Lewis K. Isoflavones as potentiators of antibacterial activity. J Agric Food Chem 2003; 51: 5677-9.
199. Gibbons S, Moser E, Kaatz GW. Catechin gallates inhibit multidrug resistance (MDR) in Staphylococcus aureus. Planta Med 2004; 70: 1240-2.
200. Sudano Roccaro A, Blanco AR, Giuliano F, Rusciano D, Enea V. Epigallocatechin-gallate enhances the activity of tetracycline in staphylococci by inhibiting its efflux from bacterial cells. Antimicrob Agents Chemother 2004; 48: 1968-73.
201. Oluwatuyi M, Kaatz GW, Gibbons S. Antibacterial and resistance modifying activity of Rosmarinus officinalis. Phytochemistry 2004; 65: 3249-54.
202. Smith E, Kaatz GW, Seo SM, Wareham N, Williamson EM, Gibbons S. The phenolic diterpene totarol inhibits multidrug efflux pump activity in Staphylococcus aureus. Antimicrob Agents Chemother 2007; 51: 4480-3.
203. Gibbons S, Oluwatuyi M, Veitch NC, Gray AI. Bacterial resistance modifying agents from Lycopus europaeus. Phytochemistry 2003; 62: 83-7.
204. Smith ECJ, Williamson EM, Wareham N, Kaatz GW, Gibbons S. Antibacterials and modulators of bacterial resistance from the immature cones of Chamaecyparis lawsoniana. Phytochemistry 2007; 68: 210-7.
205. Martins A, Vasas A, Viveiros M, Molnár J, Hohmann J, Amaral L. Antibacterial properties of compounds isolated from Carpobrotus edulis. Int J Antimicrob Agents 2011; 37: 438-44.
206. Chérigo L, Pereda-Miranda R, Gibbons S. Bacterial resistance modifying tetrasaccharide agents from Ipomoea murucoides. Phytochemistry 2009; 70: 222-7.
207. Pereda-Miranda R, Kaatz GW, Gibbons S. Polyacylated oligosaccharides from medicinal Mexican morning glory species as antibacterials and inhibitors of multidrug resistance in Staphylococcus aureus. J Nat Prod 2006; 69: 406-9.
208. Stermitz F, Halligan KM, Morel C, Tegos GP, Lewis K. Polyacylated neohesperidosides From Geranium caespitosum: bacterial multidrug resistance pump inhibitors. Bioorg Med Chem Lett 2003; 13: 1915-8.
209. Chérigo L, Pereda-Miranda R, Fragoso-Serrano M, Jacobo-Herrera N, Kaatz GW, Gibbons S. Inhibitors of bacterial multidrug efflux pumps from the resin glycosides of Ipomoea murucoides. J Nat Prod 2008; 71: 1037-45.
210. Khan IA, Mirza ZM, Kumar A, Verma V, Qazi GN. Piperine, a phytochemical potentiator of ciprofloxacin against Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50: 810-2.
211. Marquez B. Bacterial efflux systems and efflux pumps inhibitors. Biochimie 2005; 87: 1137-47.
212. Mohtar M, Johari SA, Li AR, Isa MM, Mustafa S, Ali AM, Basri DF. Inhibitory and resistance-modifying potential of plant-based alkaloids against methicillin-resistant Staphylococcus aureus (MRSA). Curr Microbiol 2009; 59: 181-6.
213. Musumeci R, Speciale A, Costanzo R, et al. Berberis aetnensis C. Presl. extracts: antimicrobial properties and interaction with ciprofloxacin. Int J Antimicrob Agents 2003; 22: 48-5.
214. Stavri M, Piddock LJV, Gibbons S. Bacterial efflux pump inhibitors from natural sources. J Antimicrob Chemother 2007; 59: 1247-60.
215. Ponnusamy K, Ramasamy M, Savarimuthu I, Paulraj MG. Indirubin potentiates ciprofloxacin activity in the NorA efflux pump of Staphylococcus aureus. Scand J Infect Dis 2010; 42: 500-5.
216. Lechner D, Gibbons S. Bucar F. Modulation of isoniazid susceptibility by flavonoids in Mycobacterium. Phytochem Lett 2008; 1: 71-5.
217. Lechner D, Gibbons S, Bucar F. Plant phenolic compounds as ethidium bromide efflux inhibitors in Mycobacterium smegmatis. J Antimicrob Chemother 2008; 62: 345-8.
218. Mossa JS, El Feraly FS, Muhammad I. Antimycobacterial constituents from Juniperus procera, Ferula communis and Plumbago zeylanica and their in vitro synergistic activity with isonicotinic acid hydrazide. Phytother Res 2004; 18: 934-7
219. Jin J, Zhang JY, Guo N, et al. Farnesol, a potential efflux pump inhibitor in Mycobacterium smegmatis. Molecules 2010; 15: 7750-62.
220. Lechner D, Gibbons S, Jachak S, Srivastava A, Bucar F. Curcuminoids as efflux pump inhibitors (EPIs) in Mycobacterium smegmatis mc2155. In: Skaltsounis L, Magiatis P Eds. Book of Abstracts-7th Joint Meeting of GA, AFERP, ASP, PSI & SIF; 2008; Athens, Greece; 2008; p. 12.
221. Piddock L, Garvey MI, Rahman MM, Gibbons S. Natural and synthetic compounds such as trimethoprim behave as inhibitors of efflux in Gram-negative bacteria. J Antimicrob Chemother 2010; 65: 1215-23.
222. Pagès J, Dimarcq JL, Quenin S, Hetru C. Thanatin activity on multidrug resistant clinical isolates of Enterobacter aerogenes and Klebsiella pneumoniae. Int J Antimicrob Agents 2003; 22: 265-9.
223. Chusri S, Villanueva I, Voravuthikunchai SP, Davies J. Enhancing antibiotic activity: a strategy to control Acinetobacter infections. J Antimicrob Chemother 2009; 64: 1203-11.